Redell M, et al. - In the post-approval setting, researchers characterized the use of oritavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) in adults by developing a patient registry. They recognized that in this older patient population with multiple co-morbid conditions, clinical and microbiologic outcomes and safety of single-dose oritavancin 1200 mg were similar to those observed in the Phase 3 SOLO trials.